Navigation Links
ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
Date:12/18/2007

e US FDA for the treatment of oral mucositis in subjects with advanced head and neck cancer. In addition to these indications, the SOD mimetics have potential therapeutic uses in a variety of inflammatory disorders including asthma, chronic obstructive pulmonary disease, and radiation protection, stroke, and ischemia reperfusion injury.

2. An antibacterial library of compounds consisting of approximately 800 small molecules, all new chemical entities (NCEs), which may be developed for the treatment of serious bacterial infections, including complicated skin and skin structure infections, endocarditis, osteomyelitis, foreign-body infections, Clostridium difficile-associated diarrhea (CDAD), as well as peptic ulcer disease due to Helicobacter pylori, and disease due to Chlamydia infections. In addition, these NCEs have the potential to be administered as topical agents for the treatment of acne and for the eradication of Staphylococcus aureus in nasal passages.

3. Rifalazil, a clinical stage compound which has been tested in approximately 600 patients, is a potent antibacterial agent with activity mainly against pathogenic Gram-positive bacteria. Rifalazil was found efficacious in a Phase II Chlamydia STD clinical trial, and, separately, a protocol has been submitted to the FDA to begin a Phase II clinical trial in carotid artery atherosclerosis. Rifalazil has been granted Fast Track designation for the treatment of CDAD. The Company has open INDs to continue rifalazil development for infectious diseases, and atherosclerosis-related disease.

Request for Further Information

Interested parties can obtain a bidder's package by contacting Joseph F. Finn, Jr., CPA (jffinnjr@earthlink.net, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. The package is intended to provide prospective purchasers with information concerning the Company's Sale of Assets and conveyancing documents. For techn
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
2. Exelixis Sells 80% Stake in Artemis to Taconic
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
5. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
9. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Atomic Force Microscopy (AFM) have been developed and are opening ... liquid/air interface. The NeedleProbes’ cylindrical geometry enables researchers to ... viscosity - all in a single force distance curve. ... ... New, constant diameter NeedleProbes are enabling unique measurements ...
(Date:12/15/2009)... 15 The Center for Business ... is pleased to announce the full agenda ... and Reporting Congress . The forum will ... March 16-17, 2010. ,, Over 1,500 senior-level ... attended this premier event since its inception, ...
(Date:12/15/2009)... -- , - 45 ... Ability of,Cardiopoietic Cells to Restore Cardiac Function ,, ... Belgian biotechnology company specialising,in cell-based therapies for the ... completed, two months ahead of schedule,enrolment in the ... of C-Cure, a,unique stem cell therapy for heart ...
(Date:12/14/2009)... Calif., Dec. 14 Vermillion, Inc. ... today announced William C. Wallen, Ph.D. Chief ... Development for IDEXX Laboratories, will be joining ... Vermillion,s bankruptcy plan. ,, "Bill brings ... experience in diagnostics and biotechnology," said Gail ...
Breaking Biology Technology:New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4
... LCM Staining Kit , , ... protocols optimized to minimize endogenous RNase activity , ... histological and fluorescent stains , Designed for use , ... , Compatible with Arcturus LCM Systems ...
... in conjunction , with a fluorometer ... ultra-sensitive assay for determining RNase A specific activity. The , ... , including RNase A, T1, RNase ... mung bean nuclease, and Benzonase. In addition to detecting , ...
... , ... polymerase chain reaction-based technique developed to facilitate , ... href="http://www.ambion.com/techlib/tn/73/731.html#end">"Who Needs , ... is a major , improvement ...
Other Biology Technology:Protect RNA and Improve Target Cell Identification 2Protect RNA and Improve Target Cell Identification 3Protect RNA and Improve Target Cell Identification 4Protect RNA and Improve Target Cell Identification 5Protect RNA and Improve Target Cell Identification 6Measuring RNase Activity A Real-time Kinetic Analysis 2Measuring RNase Activity A Real-time Kinetic Analysis 3Measuring RNase Activity A Real-time Kinetic Analysis 4Measuring RNase Activity A Real-time Kinetic Analysis 5Get the 5'-End 2Get the 5'-End 3Get the 5'-End 4Get the 5'-End 5Get the 5'-End 6Get the 5'-End 7
(Date:12/16/2009)... Hill, CA Tom Bowman, an expert in communicating ... Global Change, has developed a series of graphics that ... Climate Change (IPCC) report for public audiences. These new ... they need to make informed decisions about climate change ... as a means to clearly and accurately communicate findings ...
(Date:12/16/2009)... PALM HARBOR, Fla., Dec. 2 ... CICI), a leading supplier of electronic signature ... financial industry* and the recognized leader** in ... ("Docubase"), a leading International Electronic Document Management ... have entered an agreement to provide their ...
(Date:12/16/2009)... Va., Dec. 9 CSC (NYSE: ... the American Association for Laboratory Accreditation awarded ... (ISO/IEC) 17025:2005 accreditation to the company,s Test ... Identity Labs located in Fairmont, W.Va. The ... laboratory in the world to achieve this ...
Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 1Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 3Diabetes drug linked to increased risk of heart failure 54955 1Diabetes drug linked to increased risk of heart failure 54955 2Smokeless tobacco increases risk of heart attack and stroke 54953 1
... reign of a honey bee queen appears to be ... times she mates with drone bees. , That ... Entomology and W.M. Keck Center for Behavioral Biology at ... post-doctoral research associate; Dr. David Tarpy, assistant professor and ...
... laboratories may grow synthetically engineered tissues such as muscle ... forward, Cornell engineers describe in the journal Nature ... can nourish growing tissues., The researchers have engineered tiny ... system at the cellular scale and can supply oxygen, ...
... Which came first, the chicken genome or the egg genome? ... relevant) genomic question: Which of the thousands of long stretches ... which are the duplicates? , The answers, published online by ... first evolutionary history of the duplications in the human genome ...
Other Biology News:For honey bee queens, multiple mating makes a difference 2For honey bee queens, multiple mating makes a difference 3Researchers create system to build transplant tissue 2Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
Biology Products: